Ono Pharmaceutical Co., Ltd. (TYO:4528)
Japan flag Japan · Delayed Price · Currency is JPY
1,641.00
-49.50 (-2.93%)
Aug 1, 2025, 3:30 PM JST

Ono Pharmaceutical Company Description

Ono Pharmaceutical Co., Ltd. engages in production, purchase, and sale of pharmaceuticals and diagnostic reagents worldwide.

It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia.

It also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, for the treatment of Secondary Hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.

In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis.

The company has a collaboration with Adimab, LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders.

The company was founded in 1717 and is headquartered in Osaka, Japan.

Ono Pharmaceutical Co., Ltd.
CountryJapan
Founded1717
IndustryDrug Manufacturers - General
SectorHealthcare
Employees4,287
CEOGyo Sagara

Contact Details

Address:
8-2, Kyutaromachi 1-chome
Osaka, 541-8564
Japan
Phone81 6 6263 5670
Websiteono-pharma.com

Stock Details

Ticker Symbol4528
ExchangeTokyo Stock Exchange
Stock TypeCommon Stock
Fiscal YearApril - March
Reporting CurrencyJPY
ISIN NumberJP3197600004
SIC Code2834

Key Executives

NamePosition
Gyo SagaraChief Executive Officer
Masaki ItoChief Financial Officer
Toichi TakinoChief Operating Officer